Alnylam Pharmaceuticals has received a $2B investment from Blackstone in a mix of debt and equity intended to increase the speed at which products go to market.
“Blackstone is uniquely positioned to provide customized, one-stop-shop financing solutions at scale while establishing development collaborations with the world’s leading biotech companies. Alnylam’s RNAi technology represents one of the most promising and rapidly advancing frontiers in biology and drug development today, and aligns perfectly with our investment strategy.”
Nicholas Galakatos, Ph.D., Global Head of Blackstone Life Sciences
The move is likely the first of many for Blackstone and other private equity firms as they seek to utilize their massive cash piles while prices remain low.